Epstein Files Search

Biotechnology the expanding pipeline has a number of major call options in hepatitis B, Geoff Meacham AC NASH, IPF, hematology/oncology and now respiratory syncytial virus (RSV). Indeed ... this report as only a single factor in making their investment decision. www.jpmorganmarkets.com EFTA00300337 Geoff Meacham North America Equity Research 22 May 2014 J.PMorgan • Encouraging efficacy in phase 2a challenge ... forecast a WW opportunity at peak of -$2B. • Reiterate Overweight rating. 3 EFTA00300339 Geoff Meacham